Notice2022-07892
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 13, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 71 (Wednesday, April 13, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 71 (Wednesday, April 13, 2022)]
[Notices]
[Page 21892]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-07892]
[[Page 21892]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240-627-3705 or
<a href="/cdn-cgi/l/email-protection#99faf1ebf0eab7f2f6ebf7f8f2d9f7f0f1b7fef6ef"><span class="__cf_email__" data-cfemail="b0d3d8c2d9c39edbdfc2ded1dbf0ded9d89ed7dfc6">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Humanized Murine Monoclonal Antibodies That Neutralize Type-1
Interferon (IFN) Activity
Description of Technology
Interferons (IFNs) are a family of cytokines that function in
response to an immune challenge such as a viral or bacterial infection.
Type I IFNs are produced by immune cells (predominantly monocytes and
dendritic cells) as well as fibroblasts and signal through a specific
cell surface receptor complex (IFNAR) that consist of IFNAR1 and IFNAR2
chains. Type-I IFNs exert several common effects including antiviral,
antiproliferative, and immunomodulatory activities. However, Type I
IFNs also have pro-inflammatory effects, especially in the presence of
TNF-[alpha]. Therefore, neutralizing the pro-inflammatory effect of
Type I interferon could have wide clinical applications in autoimmune
diseases like SLE, or in acute and chronic viral diseases like SARS-
CoV-2, HIV or HCV infection, respectively, in which IFN-induced
inflammation may be detrimental.
Scientists at the National Institute of Allergy and Infectious
Diseases (NIAID) have developed two anti-IFN receptor 2 (IFNAR2)
antibodies, B7 and A10, that are effective in vitro at neutralizing
Type I IFN activities. The antibodies are comprised of two heavy chains
and two light chains of amino acids. Both antibodies are able to bind
to the extracellular domain of IFNAR2, Type I IFN receptor subunit 2,
thus suppressing IFN signaling.
Because there are no potent IFNAR2 antibodies for therapies
commercially available at this time, these antibodies are a novel
therapeutic tool that could be used exclusively or in combination to
treat chronic inflammatory diseases (like autoimmune disorders such as
SLE) in which sustained IFN production may lead to both systemic and
specific organ dysfunctions or chronic viral diseases (such as HIV,
HCV) in which sustained IFN production has deleterious effects on
immunologic function.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Therapeutics for the treatment of chronic inflammatory conditions:
<bullet> In chronic inflammatory diseases (e.g., autoimmune
disorders such as SLE).
<bullet> In chronic viral diseases (such as HIV, HCV infection).
<bullet> In acute viral or inflammatory diseases (e.g., SARS-CoV-
2).
Development Stage
<bullet> Pre-clinical.
Inventors: Paolo Lusso, M.D. Ph.D., Hana Schmeisser, Ph.D., Kathryn
C. Zoon, Ph.D., Qingbo, Liu, Ph.D., all of NIAID.
Publications:
A.N. Morrow, H. Schmeisser, T. Tsuno, K.C. Zoon. A novel role for
IFN-stimulated gene factor 3II in IFN-[gamma] induction of antiviral
activity in human cells. J Immunol 186: 1685-93, 2011.
C.A. Balinsky, H. Schmeisser, S. Ganesan, K. Singh, T.C. Pierson,
K.C. Zoon. Nucleolin interacts with the dengue virus capsid protein
and plays a role in formation of infectious virus particles. J Virol
87: 13094-106, 2013.
H. Schmeisser, S.B. Fey, J. Horowitz, E.R. Fischer, C.A. Balinsky,
K. Miyake, J. Bekisz, A.L. Snow, K.C. Zoon. Type I interferons
induce autophagy in certain human cancer cell lines. Autophagy 9:
683-96, 2013.
L.A. Zaritsky, J.R. Bedsaul, K.C. Zoon. Virus multiplicity of
infection affects type I interferon subtype induction profiles and
interferon-stimulated genes. J Virol 89 (22): 11534-48, 2015.
C.A. Balinsky, H. Schmeisser, A.I. Wells, S. Ganesan, T. Jin, K.
Singh, K.C. Zoon. IRAV (FLJ112886), an interferon stimulated gene
with antiviral activity against Dengue Virus, interacts with MOV 10.
J Virol 14: 91(5), e01606-16, 2017.
A.W.T. Chiang, S. Li, B.P. Kellman, G. Chattopadhyay, Y. Zhang, Ch.
Ch. Kuo, J.M. Gutierrez, F, Ghazi, H. Schmeisser, P. M[eacute]nard,
S.P. Bj[oslash]rn, B.G. Voldborg, A.S. Rosenberg, M. Puig, Nathan E.
Lewis. Combating viral contaminants in CHO cells by engineering
innate immunity. Sci Rep 9 (1), 8827, 2019.
Intellectual Property: HHS Reference No. E-220-2020-0; U.S.
provisional application No. 63/094,572 filed on 10/21/2020 and PCT
application PCT/US2021/056067.
Licensing Contact: To license this technology, please contact Chris
Kornak 240-627-3705 or <a href="/cdn-cgi/l/email-protection#35565d475c461b5e5a475b545e755b5c5d1b525a43"><span class="__cf_email__" data-cfemail="593a312b302a7732362b37383219373031773e362f">[email protected]</span></a>, and reference E-220-2020.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Chris Kornak at 240-627-3705 or
<a href="/cdn-cgi/l/email-protection#1172796378623f7a7e637f707a517f78793f767e67"><span class="__cf_email__" data-cfemail="a7c4cfd5ced489ccc8d5c9c6cce7c9cecf89c0c8d1">[email protected]</span></a>.
Dated: April 8, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-07892 Filed 4-12-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 13, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.